This case highlights a rare but severe bleeding complication (hemorrhagic pericarditis with cardiac tamponade) associated with abciximab use during PCI.
Answers are grounded in this paper and cite their sources.
Clinicians should remain vigilant for rare abciximab-related tamponade post-PCI; case reports leave incidence and prevention strategies open.
Glycoprotein (GP) IIb/IIIa inhibitors, such as abciximab, are used as adjunctive therapy for percutaneous coronary intervention (PCI) in high-risk non-ST-elevation myocardial infarction (NSTEMI) and in ST-elevation myocardial infarction (STEMI), although their effects when used for STEMI are less clear. As the use of GP IIb/IIIa inhibitors becomes more widespread, determining the risks associated with them becomes more important. The major risks associated with the use of GP IIb/IIIa inhibitors are the potential for major bleeding and thrombocytopenia. This is the first reported case in Korea of hemorrhagic pericarditis resulting in cardiac tamponade associated with the use of abciximab, a commonly used GP Ilb/IIa inhibitor, following PCI.
No takes yet. Share an insight, caveat, or question.
Moon et al. (2008) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: